Brokerages expect Cardlytics Inc (NASDAQ:CDLX) to post sales of $44.01 million for the current quarter, according to Zacks. Five analysts have issued estimates for Cardlytics’ earnings. The lowest sales estimate is $43.56 million and the highest is $44.58 million. Cardlytics posted sales of $39.27 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.1%. The company is scheduled to issue its next earnings report on Monday, March 18th.

According to Zacks, analysts expect that Cardlytics will report full-year sales of $147.08 million for the current financial year, with estimates ranging from $146.43 million to $148.00 million. For the next fiscal year, analysts expect that the firm will post sales of $198.02 million, with estimates ranging from $184.00 million to $210.12 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Cardlytics.

Cardlytics (NASDAQ:CDLX) last issued its earnings results on Tuesday, November 13th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.48. The company had revenue of $34.58 million for the quarter, compared to analyst estimates of $37.62 million. The business’s quarterly revenue was up 10.1% compared to the same quarter last year.

Several research analysts have weighed in on CDLX shares. Zacks Investment Research upgraded shares of Cardlytics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Monday, November 19th. SunTrust Banks reaffirmed a “buy” rating and issued a $27.00 price target on shares of Cardlytics in a report on Tuesday, September 11th. Bank of America reaffirmed a “hold” rating and issued a $22.00 price target on shares of Cardlytics in a report on Friday, August 17th. Raymond James reduced their price target on shares of Cardlytics from $23.00 to $20.00 and set an “outperform” rating on the stock in a report on Wednesday, November 14th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Cardlytics from $31.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, November 14th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Cardlytics has a consensus rating of “Buy” and a consensus price target of $23.25.

CDLX traded down $0.52 on Tuesday, hitting $13.51. 140,769 shares of the company were exchanged, compared to its average volume of 153,456. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.91. Cardlytics has a fifty-two week low of $11.10 and a fifty-two week high of $28.29. The firm has a market capitalization of $273.77 million and a P/E ratio of -1.68.

In other Cardlytics news, Director Polaris Venture Management Co. sold 150,000 shares of the company’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $25.04, for a total value of $3,756,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Several institutional investors and hedge funds have recently made changes to their positions in CDLX. Wells Fargo & Company MN lifted its stake in shares of Cardlytics by 72.4% during the third quarter. Wells Fargo & Company MN now owns 8,004 shares of the company’s stock valued at $201,000 after buying an additional 3,361 shares during the period. TIAA CREF Investment Management LLC purchased a new position in shares of Cardlytics during the third quarter valued at approximately $202,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Cardlytics during the second quarter valued at approximately $214,000. Rockefeller Capital Management L.P. purchased a new position in shares of Cardlytics during the third quarter valued at approximately $231,000. Finally, Teachers Advisors LLC purchased a new position in shares of Cardlytics during the third quarter valued at approximately $263,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.